Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following conditions or symptoms are excluded:
• •Current active clinical tuberculosis, confirmed or suspected, or household contact with someone with active clinical tuberculosis.
• •History of sensitivity/intolerance to the study medication.
• •Evidence of peripheral neuropathy, i.e., signs or symptoms of paresis, paresthesias, neuromotor abnormalities, or neurosensory deficits of grade 3 or worse.
• •Evidence of acute hepatitis.
• •Concurrent Medication:
• •Excluded:
• •\-
• •Quinolones, fluoroquinolones, or aminoglycosides with antituberculous activity (may be used for up to 14 days for treatment of intercurrent infection). Other agents with known or potential antituberculosis activity should be avoided, including the following:
• •Aminosalicylic acid salts, capreomycin, clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin, pyrazinamide, rifabutin, rifampin, streptomycin, or thiacetazone.
• •Prior Medication:
• •Excluded:
• •Treatment for more than 1 month (continuous or cumulative) with drugs that have known or potential antituberculous activity, other than quinolones, fluoroquinolones, and some aminoglycosides.
• •Patients may not have:
• •Current active clinical tuberculosis, confirmed or suspected, or household contact with someone with known active clinical tuberculosis.
• •Evidence of peripheral neuropathy, i.e., signs or symptoms of paresis, paresthesias, neuromotor abnormalities, or neurosensory deficits of grade 3 or worse.
• •Unable or unwilling to have current therapy and/or concomitant medications changed to avoid serious interaction with study medication.
• •Documented history of a positive PPD skin test.
• •Participation in other clinical trials in which there is potential activity of other study drugs against M. tuberculosis, additive toxicities between study agents, or known possible drug interactions between study drugs.
• •Alcohol or injectable drug users.